Earnings summaries and quarterly performance for BRISTOL MYERS SQUIBB.
Executive leadership at BRISTOL MYERS SQUIBB.
Christopher Boerner
Detailed
Chief Executive Officer
CEO
Cristian Massacesi
Detailed
Executive Vice President, Chief Medical Officer and Head of Development
David Elkins
Detailed
Executive Vice President and Chief Financial Officer
Karin Shanahan
Detailed
Executive Vice President, Global Product Development & Supply
Sandra Leung
Detailed
Executive Vice President and General Counsel
Board of directors at BRISTOL MYERS SQUIBB.
Deepak Bhatt
Detailed
Director
Derica Rice
Detailed
Director
Julia Haller
Detailed
Director
Karen Vousden
Detailed
Director
Manuel Hidalgo
Detailed
Director
Michael McMullen
Detailed
Director
Paula Price
Detailed
Director
Peter Arduini
Detailed
Director
Phyllis Yale
Detailed
Director
Theodore Samuels
Detailed
Lead Independent Director
Research analysts who have asked questions during BRISTOL MYERS SQUIBB earnings calls.
Christopher Schott
JPMorgan Chase & Co.
6 questions for BMY
Also covers: ABBV, AMGN, AMRX +15 more
Courtney Breen
AllianceBernstein
6 questions for BMY
Also covers: ABBV, AMGN, GILD +4 more
David Risinger
Leerink Partners
6 questions for BMY
Also covers: ABBV, AMGN, HALO +9 more
Evan Seigerman
BMO Capital Markets
6 questions for BMY
Also covers: ABBV, AMGN, ARVN +15 more
Luisa Hector
Berenberg
6 questions for BMY
Also covers: ABBV, AZN, MRK +1 more
Akash Tewari
Jefferies
5 questions for BMY
Also covers: ALKS, APLS, ARGX +15 more
Carter L. Gould
Barclays
5 questions for BMY
Also covers: ABBV, ALEC, AMGN +7 more
Mohit Bansal
Wells Fargo & Company
5 questions for BMY
Also covers: ABBV, AMGN, BMRN +16 more
Steve Scala
Cowen
5 questions for BMY
Also covers: ABBV, AZN, GSK +6 more
Asad Haider
Goldman Sachs
4 questions for BMY
Also covers: ABBV, BNTX, JNJ +4 more
James Shin
Analyst
4 questions for BMY
Also covers: ABBV, AMGN, AUTL +7 more
Seamus Fernandez
Guggenheim Partners
4 questions for BMY
Also covers: AMLX, ARCT, ARQT +9 more
Terence Flynn
Morgan Stanley
4 questions for BMY
Also covers: ABBV, AMGN, ARVN +17 more
David Amsellem
Piper Sandler Companies
3 questions for BMY
Also covers: ABBV, ALKS, AMGN +27 more
Geoff Meacham
Citigroup Inc.
3 questions for BMY
Also covers: ABBV, AMGN, GILD +8 more
Matthew Phipps
William Blair
3 questions for BMY
Also covers: ABBV, AGEN, AMGN +8 more
Sean McCutcheon
Raymond James
3 questions for BMY
Also covers: CMPX, CRIS, CYTK +6 more
Chris Shibutani
Goldman Sachs Group, Inc.
2 questions for BMY
Also covers: ABBV, ALKS, BNTX +11 more
Geoffrey Meacham
Citi
2 questions for BMY
Also covers: ABBV, BIIB, GILD +6 more
Olivia Brayer
Cantor
2 questions for BMY
Also covers: AMGN, AUPH, BMRN +8 more
Tim Anderson
Bank of America
2 questions for BMY
Also covers: ABBV, AMLX, BIIB +4 more
Timothy Anderson
BofA Securities
2 questions for BMY
Also covers: ABBV, AMGN, AZN +10 more
Alexandria Hammond
Wolfe Research
1 question for BMY
Also covers: ABBV, AMGN, BMRN +6 more
Chun Chen
UBS
1 question for BMY
Crypta Devarakonda
Truist Securities
1 question for BMY
Kripa Devarakonda
Truist Securities
1 question for BMY
Also covers: ABCL, ARVN, INCY +5 more
Srikripa Devarakonda
Truist Financial Corporation
1 question for BMY
Also covers: ABCL, ABSI, AFMD +12 more
Steven Scala
TD Cowen
1 question for BMY
Also covers: NVS
Trang Han
UBS
1 question for BMY
Trung Huynh
UBS Group AG
1 question for BMY
Also covers: ABBV, ABOS, AMGN +5 more
Recent press releases and 8-K filings for BMY.
Bristol Myers Squibb announces U.S. agreement on Eliquis affordability
BMY
New Projects/Investments
- BMS to provide Eliquis free to Medicaid for a 3-year period starting January 1, 2026 under a new agreement.
- Agreement includes donation of over seven tons of Eliquis API to the U.S. Strategic Active Ingredient Reserve.
- BMS will receive 3 years of tariff relief and be exempt from future pricing mandates.
- Commitment to balanced pricing for new launches and ~80% off list prices for direct-to-patient access to Sotyktu, Zeposia, Reyataz, Baraclude, and Orencia.
2 days ago
Bristol Myers Squibb outlines next wave of hematology assets
BMY
New Projects/Investments
- Bristol Myers Squibb’s drug development in hematology is anchored by three priorities—science, execution, and value—and driven by two complementary platforms: targeted protein degradation and cell therapy.
- The CELMoD iberdomide, in combination with daratumumab and dexamethasone for newly diagnosed multiple myeloma patients not receiving transplant, achieved 95% ORR, 68% CR, and MRD negativity in over two-thirds of patients at 22 months.
- Mezigdomide plus a proteasome inhibitor and dexamethasone demonstrated ORR > 80% in patients with 1–2 prior lines and > 70% ORR in heavily pretreated patients, supporting pivotal SUCCESSOR-1 and -2 trials.
- Arlo-cel, the GPRC5D-targeting CAR-T, showed ORR > 90% and MRD-negative CR in over 40% of heavily pretreated relapsed/refractory multiple myeloma patients at nearly two years of follow-up.
- Breyanzi became the first CAR-T approved for marginal zone lymphoma—across five cancer types—and achieved number-one worldwide CD19 CAR-T sales aided by expanded manufacturing capacity.
Dec 11, 2025, 2:00 PM
Bristol Myers Squibb outlines next-wave hematology updates
BMY
- BMS highlights leadership in hematology through two platforms: targeted protein degradation (CELMoDs) and cell therapy with two approved CAR-T therapies, Abecma and Breyanzi, plus pipelines in Phase 3 and early trials.
- Iberdomide and Mezigdomide, pivotal-stage CELMoDs, are advancing in Phase 3 (EXCALIBER-RRMM, SUCCESSOR-1/2) after early data showed Iberdaradex ORR 95%, CR 68%, and MRD negativity > 66%.
- Golcadomide, a first-in-class CELMoD degrader, demonstrated front-line combo efficacy (24-month PFS ~ 79%, DOR > 90%) supporting ongoing Phase 3 GOLSEEK-1 and GOLSEEK-4 trials in LBCL and FL.
- Breyanzi became the #1 global CD19 CAR-T, driven by manufacturing scale-up, differentiated safety profile, and broader indications, while dual BCMA/GPRC5D CAR-T data are expected next year.
Dec 11, 2025, 2:00 PM
Bristol Myers Squibb outlines next‐generation hematology pipeline
BMY
- Bristol Myers Squibb is focusing on two core platforms in hematology: targeted protein degradation (CELMoDs, ligand-directed degraders, degrader ADCs) and cell therapy (two approved CAR-T products plus next-generation assets).
- Two pivotal‐stage CELMoDs, Iberdomide (EXCALIBER-RRMM) and Mezigdomide (SUCCESSOR-1/2), are in phase 3 with PFS top-line data expected next year.
- ArloCell, a first-in-class GPRC5D CAR-T, demonstrated >90% ORR and >40% MRD-negative CRs in heavily pretreated multiple myeloma; pivotal Quintessential readout expected next year.
- In lymphoma, golcadomide plus R-CHOP achieved 79% 24-month PFS, while the BCL6 ligand-directed degrader showed 65% ORR in DLBCL and FL; phase 3 GOLSEEK data slated for 2028.
- Multiple pivotal and early-stage readouts across these platforms are anticipated in 2026–2028, underpinning BMS’s hematology growth trajectory.
Dec 11, 2025, 2:00 PM
Bristol Myers Squibb unveils new lymphoma research data at ASH 2025
BMY
- Bristol Myers Squibb presented new targeted protein degradation and cell therapy data for lymphoma at ASH 2025.
- Two-year follow-up of golcadomide + R-CHOP showed 79% PFS, 88% CMR, and 90% MRD negativity.
- Golcadomide + rituximab in relapsed/refractory FL achieved 97% ORR and 78% CRR; in DLBCL, 58% ORR and 44% CRR.
- BMS-986458 monotherapy in heavily pre-treated NHL yielded a 65% ORR (54% DLBCL, 80% FL) and 21% CRR (7% DLBCL, 40% FL).
- Long-term Breyanzi results: four-year TRANSFORM landmark PFS 52.2%, OS 61.5%; three-year TRANSCEND FL CR 94%, 36-month PFS 68%.
Dec 8, 2025, 9:30 PM
Bristol Myers Squibb’s Breyanzi approved for relapsed marginal zone lymphoma
BMY
Product Launch
- The FDA approved lisocabtagene maraleucel (Breyanzi) as the first CD19-directed CAR T therapy for adults with relapsed/refractory marginal zone lymphoma after ≥2 prior systemic treatments .
- In the TRANSCEND FL trial, Breyanzi achieved a 95.5% overall response rate and 62.1% complete response rate among 66 patients at a median 21.6-month follow-up .
- Safety was manageable, with 76% cytokine release syndrome (4% grade 3; no grade 4/5) and 33% neurologic events (4% grade 3; no grade 4/5) .
- This marks Breyanzi’s fifth FDA approval, extending its indications to five B-cell malignancies and adding authorizations in major international markets .
Dec 5, 2025, 5:14 AM
Bristol Myers Squibb outlines growth portfolio and pipeline at Citi Healthcare Conference
BMY
Product Launch
New Projects/Investments
- CFO David Elkins said the growth portfolio now accounts for >50% of revenues (up 18% YoY), with four products annualizing over $1 billion (Reblozyl >$2 billion). He reiterated targets for 10 new NMEs and 30 additional indications by 2030, backed by $17 billion cash and $1 billion of efficiency savings per year through 2027.
- CCO Adam Lenkowsky reported Cobenfy’s weekly prescriptions (TRXs) approaching 2,700, outpacing recent schizophrenia launches, supported by strong Medicaid, Medicare, and commercial access.
- The ADEPT Alzheimer’s psychosis program—including four Phase 3 trials—remains on track for a late-2026 readout, while additional Phase 3/4 studies in bipolar mania, autism irritability, and Alzheimer’s agitation and cognition are already underway.
- BMS is advancing mid-late stage assets (Milvexian stroke prevention & AFib readouts in 2026; LPA1 in pulmonary fibrosis; CELMoDs Iberdomide/Mezigdomide) and expanding modality breadth through partnerships with Orbital (in vivo cell therapy), radiopharmaceuticals (Philochem), and BioNTech (VEGF/PD-1 combinations).
Dec 4, 2025, 2:00 PM
Bristol-Myers Squibb outlines Cobenfy progress and portfolio strategy
BMY
- Cobenfy ADEPT II study will continue with enrollment increased to ~400 patients after FDA and DMC review; full program readouts expected late 2026, and weekly schizophrenia TRxs have risen to ~2,700, nearing a 3,000 TRx weekly run rate—best in recent launches.
- The growth portfolio now comprises over 50% of revenues, with four products annualizing >$1 billion (Reblozyl >$2 billion); 2026 catalysts include Phase III data for iberdomide, mezigdomide, LPA1 in pulmonary fibrosis, and milvexian readouts in stroke prevention and AFib.
- Efficiency programs delivered $1 billion in savings in 2025, with a further $1 billion targeted by 2027, bolstering cash flow and funding for BD and new launches.
- AI is being deployed across discovery, clinical design, manufacturing predictability and back-office automation to accelerate timelines, improve success rates and drive further cost efficiencies.
Dec 4, 2025, 2:00 PM
Bristol Myers Squibb outlines 2026 growth priorities and pipeline at Citi Healthcare Conference
BMY
M&A
New Projects/Investments
- Growth portfolio now represents over 50% of total revenue, growing 18% in Q3 2025, with four products annualizing above $1 billion and Reblozyl exceeding $2 billion.
- Pipeline poised for 10 new NMEs and 30 additional indications by 2030, with key 2026 catalysts including iberdomide and mezigdomide (CELMoDs), LPA1 in pulmonary fibrosis, and late-stage Milvexian trials in secondary stroke prevention and AFib.
- Deployment of AI across R&D, manufacturing, and internal processes is driving $1 billion in cost savings in 2025, with another $1 billion targeted for 2026–2027.
- Commercial momentum includes Cobenfy approaching 2,700 weekly TRXs with strong Medicaid/Medicare access, and Opdivo’s subcutaneous “Cuvantic” formulation gaining accelerated conversion post–J-code implementation.
- Strategic business development advances cell therapy via Orbital acquisition and a BioNTech PD-1/VEGF mRNA partnership, and expands the radiopharmaceutical portfolio with Philochem, alongside sourcing innovative assets globally including China.
Dec 4, 2025, 2:00 PM
Bristol Myers expands ADEPT-2 Alzheimer's study after data review
BMY
New Projects/Investments
- Bristol Myers Squibb will delay ADEPT-2 study results for Cobenfy until end of 2026 to enroll additional patients after inconsistencies at certain trial sites were identified.
- The trial is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study with primary endpoints on NPI-C Hallucinations & Delusions and secondary endpoints including CGI-S.
- Bristol Myers maintains its FDA filing schedule, expecting cumulative ADEPT‐1 and ADEPT-4 results by the end of 2026 despite the ADEPT-2 delay.
- Cobenfy, already approved for schizophrenia, aims to be the first treatment for agitation and psychosis in Alzheimer’s via muscarinic receptor agonism; Bristol Myers reported $48.03 billion in revenue and a 23.78% operating margin, with ~70% of sales in the U.S..
- Shares rose about 5% to $50.76 in morning trading, reflecting cautious investor optimism.
Dec 3, 2025, 1:31 PM
Quarterly earnings call transcripts for BRISTOL MYERS SQUIBB.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more